Data integrity inspections that have disrupted pharmaceutical exports from India to the US and Europe are spreading to exporters in China and other countries, as well as to domestic US and European manufacturers that may be unprepared for them.
Even as the US Food and Drug Administration warns global manufacturers against complacency, there are indications that they remain vulnerable...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?